Then came a shocking heresy to this ‘need for NIH science’ belief system in 1998. A private company funded by ‘greedy’ investors called Celera had access to a new DNA sequencer from Applied Biosystems that could complete the human genome in a few years for 1/10th of the price. Celera’s stated interest in patenting 300 of the most valuable genes in the course of their sequencing investment became their vilifying trademark. With competition came speciation. Celera focused on speed and diversity, while the NIH focused on quality and rapid data release. Both succeeded. Fast forward to 2013 and the NIH presently has more gene patents in-force than Celera. The toll free “New Deal” has now become the 10th largest in-force gene patent estate2, 3, all funded through price mechanism-free taxes.